Table of Contents
1. DelveInsight Report Introduction
2. Zelboraf Overview
2.1 Market Competition
2.3 Competitors in Development
3 Global Sales Assessment
3.1 Historical Sales of Somavert
3.2 Forecasted Sales of Somavert
4 Product Description
4.1 Mechanism of Action
4.2 Pharmacodynamic Properties
4.3 Pharmacokinetic Properties
5 Marketed Details
5.1 United States
5.2 Europe
6 Patent Information
6.1 Patent Numbers and Expiry Details
6.2 Patent and Exclusivity Expiry Assessment United States (US)
6.3 Patent Details
7 Route of Synthesis
8 Global API Manufacturers Assessment
8.1 The United States Drug Master File (US DMF)
8.2 The Europe Drug Master File (EUDMF)/Active Substance Master File (ASMF)
8.3 The Active Pharmaceutical Ingredient (API) Manufacturers in China
8.4 The Active Pharmaceutical Ingredient (API) Manufacturers in India
9 Generic Players
10 The Pipeline Coverage
11 Clinical Trials Information
11.1 Clinical Trials by Zone
12 Company Profile
12.1 Company Summary
12.2 Company Financials
13 SWOT Analysis
14 References
15 Appendix
16 Methodology
17 Consulting Services
18 About DelveInsight
19 Contact Us
20 Disclaimer
• Table 1: Zelboraf, Historical Global Sales (in million USD), 2016
• Table 2: Zelboraf, Forecasted Global Sales (in million USD), 2016
• Table 3: Zelboraf, Description
• Table 4: Zelboraf, Marketed Details the United States (US)
• Table 5: Zelboraf, Marketed Details the Europe (EU)
• Table 6: Zelboraf, Patent/Exclusivity Expiry (Year), 2016
• Table 7: Zelboraf, Patent Number Specific Patent Expiry (Year), 2016
• Table 8: Zelboraf, Patent Details
• Table 9: Zelboraf, Route of Synthesis
• Table 10: Zelboraf, the United States Drug Master File (US DMF), 2016
• Table 11: Zelboraf, the Europe Active Substance Master File (ASMF), 2016
• Table 12: Zelboraf, the API Manufacturers, China, 2016
• Table 13: Zelboraf, the API Manufacturers, India, 2016
• Table 14: Zelboraf, Generic Players, 2016
• Table 15: Zelboraf, Pipeline Drug Details, 2016
• Table 16: Zelboraf, Clinical Trials, 2016
• Table 17: Zelboraf, Clinical Trials by Zone, 2016
• Table 18: Company Overview, 2016
• Table 19: Zelboraf, SWOT Analysis, 2016
List of Figures
• Figure 1: Zelboraf, Historical Global Sales (in million USD), 2016
• Figure 2: Zelboraf, Forecasted Global Sales (in million USD), 2016
• Figure 3: Zelboraf, Patent/Exclusivity Expiry (Year), 2016
• Figure 4: Zelboraf, Patent Number Specific Patent Expiry (Year), 2016
• Figure 5: Zelboraf, Route of synthesis
• Figure 6: Zelboraf, the API Manufacturers by the US DMF Status (%), 2016
• Figure 7: Zelboraf, the API Manufacturers by Region, 2016
• Figure 8: Zelboraf, the API Manufacturers by Location/Countries, 2016
• Figure 9: Zelboraf, Generic Players, 2016
• Figure 10: Zelboraf, Clinical Trials by Zone (%), 2016
【レポートのキーワード】
Zelboraf、医薬品、薬剤、特許、販売量、市場規模、原薬メーカー
【免責事項】
http://www.globalresearch.jp/disclaimer